Alpha Tau Medical Ltd - Asset Resilience Ratio
Alpha Tau Medical Ltd (DRTS) has an Asset Resilience Ratio of 65.79% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Alpha Tau Medical Ltd's Asset Resilience Ratio has changed over time. Check Alpha Tau Medical Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Alpha Tau Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Alpha Tau Medical Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $68.88 Million | 65.79% |
| Total Liquid Assets | $68.88 Million | 65.79% |
Asset Resilience Insights
- Very High Liquidity: Alpha Tau Medical Ltd maintains exceptional liquid asset reserves at 65.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alpha Tau Medical Ltd Industry Peers by Asset Resilience Ratio
Compare Alpha Tau Medical Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Alpha Tau Medical Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Alpha Tau Medical Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 53.22% | $45.88 Million | $86.20 Million | -11.16pp |
| 2023-12-31 | 64.37% | $69.13 Million | $107.39 Million | -17.77pp |
| 2022-12-31 | 82.14% | $98.69 Million | $120.15 Million | +63.00pp |
| 2021-12-31 | 19.14% | $8.08 Million | $42.22 Million | -38.26pp |
| 2020-12-31 | 57.40% | $30.42 Million | $52.99 Million | -25.93pp |
| 2019-12-31 | 83.33% | $26.30 Million | $31.56 Million | -- |
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending cl… Read more